Resources

Find the latest news about Femasys, including our media mentions, scientific publications, and more.

Women’s Healthcare: Will Changing Laws Inhibit Latest Innovations in Fertility and Birth Control Treatments?

Femasys CEO Talks Results of the Femaseed Pivotal Trial and the History of Fembloc Birth Control

Register Now: Femasys Webcast at the Jones Healthcare Seaside Summit 2024

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says

‘Don’t Just Give Out the Work — Do the Work’: How This Women’s Healthcare CEO Leads With Passion

Femasys Creates Products and Procedures for the Fallopian Tubes

Advancements in Technologies Changing Reproductive Healthcare with Kathy Lee-Sepsick

Femasys Inc: Putting the Focus on Women’s Reproductive Health

Femasys: Revolutionizing Female Reproduction (NASDAQ:FEMY)

Anne Morrissey Joins Femasys as a New Board Member to Help Advance FEMASEED into Clinical Development

Women’s Health Company Femasys Files for $40M IPO

Femasys Targets Male Infertility with Updated Trial Design

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

Tech Companies Working On Contraception Face A New Landscape After Roe

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

FemCerv®: Well-designed technology that can minimize patient discomfort

The Post-Roe Fertility Journey

Women’s Healthcare: Will Changing Laws Inhibit Latest Innovations in Fertility and Birth Control Treatments?

Femasys CEO Talks Results of the Femaseed Pivotal Trial and the History of Fembloc Birth Control

Register Now: Femasys Webcast at the Jones Healthcare Seaside Summit 2024

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says

Indiana reports 98% drop in abortions after curbs

VIDEO: President and CEO, Kathy Lee-Sepsick speaks to connecting with the audience

VIDEO: President and CEO, Kathy Lee-Sepsick at SLS

VIDEO: Femasys KOL Event

Media Kits

For additional information, please email media@femasys.com